From Startup Neon Therapeutics
CAMBRIDGE, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) — Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, President and Chief Executive Officer of Neon, will present at the following upcoming investor conferences:
Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 1:00 p.m. ET in New York, NY.
2018 Cantor Global Healthcare Conferenceon Wednesday, October 3, 2018 at 2:15 p.m. ET in New York, NY.
A live webcast of each of these presentations will be available by visiting the Investors section of Neon Therapeutics’ website at ir.neontherapeutics.com. A replay of each of these webcasts will be archived on the Neon Therapeutics website for 30 days following the presentation.
About Neon Therapeutics
Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Neon is using its neoantigen platform to develop both vaccine and T cell therapies, including NEO-PV-01, a clinical stage neoantigen vaccine for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of a subset of estrogen-receptor-positive breast cancer.
For more information, please visit www.neontherapeutics.com.
Media Contact:Stephanie Simon, Ten Bridge Communicationsstephanie@tenbridgecommunications.com617-581-9333
Investor Contact:Will O’Connor, Stern Investor Relationswill@sternir.com212-362-1200
Source: Neon Therapeutics, Inc.
Please visit their site for more information: NeonTherapeutics.com